US2007134729A1PendingUtilityA1

Novel antibacterial agents

Individually held — no corporate assignee on recordPriority: Jun 8, 1998Filed: Nov 21, 2006Published: Jun 14, 2007
Est. expiryJun 8, 2018(expired)· nominal 20-yr term from priority
C07C 271/20A61P 37/02A61K 47/54C07D 233/90C07D 473/00C07D 471/14C07D 473/34C07D 401/14Y10S530/807G01N 33/6842C12Q 1/533A61K 47/55A61P 5/14A61P 43/00C07D 215/56C07C 323/12A61K 47/552G01N 33/6845C07D 487/06C07D 475/04C12Q 1/48C07D 475/08C07D 493/06C07C 237/24G01N 2500/04C07D 493/04C12Q 1/44C40B 30/04C07D 471/04C07D 401/12G01N 2800/044G01N 33/92C07D 487/04C07C 335/08C07C 321/04A61P 31/04C07D 207/333G01N 2500/00C07C 233/36C07D 405/04A61P 3/10A61K 31/00A61K 47/60C40B 40/04C07D 235/30C07H 19/20C07C 2603/18C07D 413/14G01N 33/573C07C 233/78C07D 211/58C07C 335/32A61P 31/18C12Q 1/26C07D 401/06Y02A50/30
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands in their monovalent (i.e., unlinked) state have the ability to bind to a an enzyme involved in cell wall biosynthesis and metabolism, a precursor used in the synthesis of the bacterial cell wall and/or the bacterial cell surface thereby interfere with the synthesis and/or metabolism of the cell wall. In particular the multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands has a ligand domain capable of binding to penicillin binding proteins, a transpeptidase enzyme, a substrate of a transpeptidase enzyme, a beta-lactamase enzyme, pencillinase enzyme, cephalosporinase enzyme, a transglycoslase enzyme, or a transglycosylase enzyme substrate; Preferably, the ligands are selected from the beta lactam or glycopeptide class of antibacterial agents.

Claims

exact text as granted — not AI-modified
1 . A multibinding compound which comprises from 2-10 ligands covalently connected by a linker or linkers wherein each of said ligands comprises a ligand domain capable of binding to penicillin binding proteins, a transpeptidase enzyme, a substrate of a transpeptidase enzyme, a beta-lactamase enzyme, a pencillinase enzyme, a cephalosporinase enzyme, a transglycoslase enzyme, or a transglycosylase enzyme substrate provided that: 
 (i) all the ligands in a multibinding compound of Formula (I) cannot be either a beta lactam antibiotic, an optionally substituted glycopeptide antibiotic, or an aglycone derivative of an optionally substituted glycopeptide antibiotic;    (ii) when p is 2 and q is 1 then at least one of the ligands is a beta lactam antibiotic; and    (iii) when p is 2, q is 1, and one of the ligands is vancomycin attached via the [C], then the other cannot be cefalexin attached to the linker via acylation of its alpha amino group.    
   
   
       2 - 40 . (canceled)

Join the waitlist — get patent alerts

Track US2007134729A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.